

CR Name	: *****	Age/Sex	: __ Yrs/ __
Referred By	: *****		
Sample On	: __/__/__	Report On	: __/__/__

CIRCULATING TUMOR CELLS COUNT

TUMOR TYPE: Colon

CHEMO STATUS: _____

RESULT:

Number of CTCs:	**
Number of nucleated cells:	****
Sample Volume:	2 ml Peripheral Blood

This CTC count is obtained in 2ml of blood.

Enrichment Platform : Microfluidic Device Celsee Prep 400

Enumeration Platform : Celsee Analyzer using Immunofluorescence.

Clinical back ground: CTC enumeration helps in determining the prognosis of a patient in breast, colon and prostate cancer. Falling CTCs before and after initiation of therapy indicates a better prognosis compared to where the counts are same or rising. CTC is an independent predictor of progression free survival and overall survival.

CTC counts were significantly higher using the Celsee PREP system, implying greater sensitivity for CTC detection.

References: Priya Gogoi, Saedah Sepehri, Yi Zhou, et al. Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. PLoS One. 2016; 11(1).

Approved By

Dr. Moushumi Suryavanshi
Head Molecular Diagnostic and Cell Biology
RGCI & RC

Please correlate the test results with clinical history of the patient. Test results are dependent on the quality of the sample received by the Laboratory. Test results are not valid for Medico legal purposes.